Accelerate Diagnostics (STU:1A80) Cash And Cash Equivalents : €13.44 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics Cash And Cash Equivalents?

Accelerate Diagnostics's quarterly cash and cash equivalents declined from Sep. 2023 (€18.89 Mil) to Dec. 2023 (€11.13 Mil) but then increased from Dec. 2023 (€11.13 Mil) to Mar. 2024 (€13.44 Mil).

Accelerate Diagnostics's annual cash and cash equivalents declined from Dec. 2021 (€35.31 Mil) to Dec. 2022 (€32.95 Mil) and declined from Dec. 2022 (€32.95 Mil) to Dec. 2023 (€11.13 Mil).

Accelerate Diagnostics Cash And Cash Equivalents Historical Data

The historical data trend for Accelerate Diagnostics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Cash And Cash Equivalents Chart

Accelerate Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

54.91

29.41

35.31

32.95

11.13

Accelerate Diagnostics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															27.47	27.03	18.89	11.13	13.44

Accelerate Diagnostics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Accelerate Diagnostics (STU:1A80) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Accelerate Diagnostics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics (STU:1A80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

AXDX:USA AXDX:Mexico 1A80:Germany

Address

3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714

Website

https://www.acceleratediagnostics.com

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (STU:1A80) Headlines

No Headlines